An Extension Study to Evaluate Casimersen or Golodirsen in Patients With Duchenne Muscular Dystrophy


Trial ID: NCT03532542


The main objective of this study is to evaluate the safety and tolerability of long-term treatment with casimersen or golodirsen in patients with Duchenne muscular dystrophy (DMD).

Official Title

Long-term, Open-label Extension Study for Patients With Duchenne Muscular Dystrophy Enrolled in Clinical Trials Evaluating Casimersen or Golodirsen

Stanford Investigator(s)

John W. Day, MD, PhD
John W. Day, MD, PhD

Professor of Neurology (Adult Neurology), of Pediatrics (Genetics) and, by courtesy, of Pathology


Inclusion Criteria:

   - Completed a clinical trial evaluating casimersen or golodirsen, per protocol.

   - Is between 7 and 23 years of age, inclusive, at enrollment.

Other inclusion/exclusion criteria apply.


drug: Casimersen

drug: Golodirsen


Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305